[HTML] nejm.org

[HTML][HTML] Dapagliflozin in patients with heart failure and reduced ejection fraction

JJV McMurray, SD Solomon, SE Inzucchi… - … England Journal of …, 2019 - Mass Medical Soc
Background In patients with type 2 diabetes, inhibitors of sodium–glucose cotransporter 2
(SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose …
被引用次数：6095 相关文章

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

JJV McMurray, SD Solomon… - The New England …, 2019 - research.regionh.dk
BACKGROUND: In patients with type 2 diabetes, inhibitors of sodium-glucose cotransporter
2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose …
[PDF] cloud-cme.com

[PDF][PDF] Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

JJV McMurray, SD Solomon… - N Engl J …, 2019 - edward-elmhurst.cloud-cme.com
BACKGROUND In patients with type 2 diabetes, inhibitors of sodium–glucose cotransporter
2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through …

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.

JJV McMurray, SD Solomon, SE Inzucchi… - The New England …, 2019 - europepmc.org
Background In patients with type 2 diabetes, inhibitors of sodium-glucose cotransporter 2
(SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose …

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

JJV McMurray, SD Solomon, SE Inzucchi… - New England Journal …, 2019 - cir.nii.ac.jp
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction | CiNii Research
CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction List of authors

JJV McMurray, SD Solomon… - … England Journal of …, 2019 - publicum.umed.lodz.pl
BACKGROUND: In patients with type 2 diabetes, inhibitors of sodium-glucose cotransporter
2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose …

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

JJV McMurray, SD Solomon, SE Inzucchi, L Køber… - dev.az-brands.com
BACKGROUND In patients with type 2 diabetes, inhibitors of sodium–glucose cotransporter
2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose …

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

JJV McMurray, SD Solomon, SE Inzucchi… - New England Journal …, 2019 - diva-portal.org
BACKGROUND In patients with type 2 diabetes, inhibitors of sodium-glucose cotransporter
2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose …

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

JJV MCMURRAY, SD SOLOMON… - … England Journal of …, 2019 - observatorio.fm.usp.br
BACKGROUND In patients with type 2 diabetes, inhibitors of sodium-glucose cotransporter
2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose …
[PDF] dapatrial.org

[PDF][PDF] Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

JJV McMurray, SD Solomon, SE Inzucchi, L Køber… - N Engl J Med, 2019 - dapatrial.org
BACKGROUND In patients with type 2 diabetes, inhibitors of sodium–glucose cotransporter
2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through …